Europe’s pharma trade with the US remains critical despite tariff turmoil

Core Insights - The article discusses the evolving landscape of the pharmaceutical trade between the US and Europe, highlighting the impact of US government policies such as the Most Favored Nation (MFN) pricing and tariffs on European pharmaceutical companies [3][6][10][17]. Group 1: US and European Pharmaceutical Trade Dynamics - The US holds a leading 40% share of global drug development, while China has a competitive 20% share, and the five major European markets collectively hold 11% [2]. - The introduction of the MFN policy by the US government in 2025 has led to concerns among pharmaceutical companies about pricing strategies in international markets [3][6]. - European pharmaceutical exports are significantly reliant on the US market, which remains the largest buyer of European pharmaceuticals [9]. Group 2: European Adaptation and Strategic Shifts - European countries are exploring alternative markets in Asia, including a free trade agreement with India that aims to eliminate tariffs on pharmaceuticals [10][12]. - Experts suggest that while Asian markets may offer cheaper alternatives, they are unlikely to replace the innovation and profit potential of the US market in the short term [4][11][17]. - The EU's Critical Medicines Act aims to reduce dependence on external suppliers, which may conflict with increased trade with Asian manufacturers [12]. Group 3: Regulatory and Policy Developments - The EU Biotech Act proposed in December 2025 aims to fund and accelerate biotech innovation, addressing challenges such as fractured regulation and shallow capital markets [18]. - The upcoming Pharma Package in 2026 will introduce updates to EU pharmaceutical law, including changes to market protection periods for new drugs [19]. - The overhaul of the US life sciences sector presents potential opportunities for European companies, particularly in areas like mRNA vaccine research [20][21].